An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre.
about
Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?Efficacy of second-line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non-small cell lung cancer without epidermal growth factor receptor mutations.Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review.
P2860
An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
An exploratory comparative ana ...... a single tertiary care centre.
@ast
An exploratory comparative ana ...... a single tertiary care centre.
@en
type
label
An exploratory comparative ana ...... a single tertiary care centre.
@ast
An exploratory comparative ana ...... a single tertiary care centre.
@en
prefLabel
An exploratory comparative ana ...... a single tertiary care centre.
@ast
An exploratory comparative ana ...... a single tertiary care centre.
@en
P2093
P2860
P356
P1433
P1476
An exploratory comparative ana ...... a single tertiary care centre.
@en
P2093
G Kasymjanova
J Peterson
P2860
P304
P356
10.3747/CO.22.2296
P577
2015-06-01T00:00:00Z